LONDON, 18 April, 2017:

Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement today by Verona Pharma, in which it has a 6.6% holding, that it has received authorisation from the Food and Drug Administration to proceed with the first clinical trial of RPL554 in the US.

RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, designed to have anti-inflammatory as well as bronchodilator properties, currently in development for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

Verona Pharma has announced that it plans to initiate the pharmacokinetic clinical trial in the middle of this year to determine the oral bioavailability of RPL554, as well as assess the safety and tolerability of the drug. Top-line data is expected in the fourth quarter of 2017.

“Verona is a dynamic company with an important drug asset, which we believe has the potential to address significant unmet needs in respiratory medicine. RPL554 has shown potential in COPD and cystic fibrosis. This authorisation by the FDA puts it on a path towards advancing this promising candidate towards approval.”

Joe Anderson, Chief Executive Officer of Arix Bioscience Plc